The Vascular Protection by Adiponectin | OMICS International | Abstract
ISSN: 2165-7904

Journal of Obesity & Weight Loss Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Special Issue Article

The Vascular Protection by Adiponectin

Jian Cui1, Qingguo Wang2 and Hanrui Zhang1*
1Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
2College of Basic Medicine, Beijing University of Chinese Medicine, Beijing 100029, China
Corresponding Author : Hanrui Zhang, MD, PhD
Cardiovascular Institute
Perelman School of Medicine
University of Pennsylvania, Philadelphia, PA 19104
Tel: 215-573-0244
Fax: 215-573-2094l
E-mail: [email protected]
Received August 02, 2012; Accepted October 23, 2012; Published October 26, 2012
Citation: Cui J, Wang Q, Zhang H (2012) The Vascular Protection by Adiponectin. J Obes Wt Loss Ther S3:001. doi:10.4172/2165-7904.S3-001
Copyright: © 2012 Cui J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Adiponectin is an adipokine mainly produced by adipose tissue. Circulating levels of adiponectin are reduced in conditions that are associated with an increased risk of cardiovascular diseases, leading to the growing research interests in the vascular protective activities of adiponectin. Adiponectin exerts multiple vascular protective effects through direct actions on endothelial cells, vascular smooth muscle cells, monocytes and macrophages, adventitial fibroblasts, and platelets. It also affects monocyte-endothelium and leukocyte-endothelium adhesion. In addition, adiponectin opposes the inflammatory, apoptotic, and atherogenic effects of other adipokines, e.g. tumor necrosis factor-alpha, resistin, and interleukin-18. Thus, it is plausible that adiponectin plays a beneficial role in the treatment and prevention of vascular dysfunction. Adiponectin and its signaling may serve as potential therapeutic targets in reducing the morbidity and mortality of cardiovascular diseases.